Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Xilio Therapeutics (Nasdaq: XLO) announced on Oct 2, 2025 that effective Oct 1, 2025 it granted non‑qualified stock options to purchase 26,000 shares to three new employees under its 2022 Inducement Stock Incentive Plan.

The options have an exercise price of $0.8326 (equal to the closing price on Oct 1, 2025), a 10‑year term, and vest 25% after 1 year with the remaining 75% vesting in 36 equal monthly installments, subject to continued service. Grants were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the plan and option agreement terms.

News Market Reaction – XLO

+2.25%

1 alert

+2.25% News Effect

+$912K Valuation Impact

$41M Market Cap

1K Volume

On the day this news was published, XLO gained 2.25%, reflecting a moderate positive market reaction. This price movement added approximately $912K to the company's valuation, bringing the market cap to $41M at that time.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2025, the company granted non-qualified stock options to purchase 26,000 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

The stock options have an exercise price of $0.8326 per share, which is equal to the closing price of the company’s common stock on October 1, 2025. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to continued service with the company or any of its subsidiaries through each applicable vesting date.

The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).

Investor Contact
investors@xiliotx.com

Media Contact
Josie Butler, 1AB
josie@1abmedia.com

FAQ

What did Xilio Therapeutics (XLO) announce on Oct 2, 2025?

Xilio granted non‑qualified stock options for 26,000 shares to three new employees effective Oct 1, 2025 under its 2022 Inducement Stock Incentive Plan.

What is the exercise price and term of the XLO inducement options?

The options have an exercise price of $0.8326 per share and a 10‑year term.

How do the XLO inducement options vest?

Vesting is 25% after 1 year then the remaining 75% vests monthly over 36 months, subject to continued service.

Why were the stock options granted under Nasdaq Listing Rule 5635(c)(4)?

They were granted as inducement awards material to hiring new employees, which Nasdaq permits under Rule 5635(c)(4).

How many employees received inducement option grants from XLO?

Three new employees received the option grants totaling 26,000 shares.

Are the XLO options subject to additional terms or agreements?

Yes, the options are subject to the 2022 Inducement Stock Incentive Plan and individual stock option agreement terms.